Kisspeptin-10
GnRH stimulator. Kisspeptin-10 is not FDA approved for any use.
Key facts
- Class
- GnRH stimulator
- Also called
- kiss
- Vial sizes sold
- 5 mg, 10 mg
- Community-reported sizes
- Half-life
- mean elimination half-life 1.3-2.2 hours
- subcutaneous (analog MVT-602), in people · Fertility and sterility 2024, PMID 37925096
- FDA status
- Not approved
- research chemical
- WADA
- Prohibited (S2.2.1)
- In and out of competition
Kisspeptin-10 guides
Explained
Questions
Evidence at a glance
Human and animal counts are PubMed records from our evidence ledger (search counts, not studies we reviewed). The grade is the strongest design among the studies we summarised for that goal: a human randomized trial outweighs any number of animal studies.
| Condition | Human studies | Animal studies | Studies we summarised | Evidence grade |
|---|---|---|---|---|
| Testosterone | 8 | 31 | 3 | Human RCT evidence, 4 of 4European journal of endocrinology 2026, PMID 42549827 |
| Menopause | 3 | 1 | 0 | No graded study for this goal |
| Liver health | 0 | 3 | 3 | Animal evidence, 2 of 4Cells 2025, PMID 40862768 |
| Fertility | Not in our ledger | Not in our ledger | 0 | No graded study for this goal |
| Men | Not in our ledger | Not in our ledger | 0 | No graded study for this goal |
| Women | Not in our ledger | Not in our ledger | 0 | No graded study for this goal |
Grades follow our evidence scale. Summarised studies come from our evidence file, each quote checked against the abstract or label.
A reproductive-axis signal, not a growth hormone releaser
Kisspeptin-10 stimulates luteinizing hormone and increases LH pulse frequency in men.[16]
The response is not uniform: kisspeptin-10 failed to stimulate gonadotropin release in women during the follicular phase.[17]
The strongest finding is acute; chronic dosing is the open question
A recent trial in healthy men found acute subcutaneous infusions dose-dependently raised LH, FSH and testosterone.[4]
After 5 days of continuous kisspeptin-10, testosterone stayed elevated but gonadotropins were similar to vehicle.[4]
In women with hypothalamic amenorrhea, kisspeptin-54 responses were significantly reduced by the 14th injection day.[18]
In women with hypothalamic amenorrhea, twice-weekly kisspeptin-54 injections gave significantly elevated reproductive hormone levels after 8 weeks compared with saline.[19]
Regulatory path
Drugs@FDA has no kisspeptin product.[2]
FDA's significant-safety-risk table lists kisspeptin-10 as a 503A substance, dated September 29, 2023.[3]
WADA's list names kisspeptin and its agonist analogues among testosterone-stimulating peptides in males.[1]
Compared with
Common stacks
Kisspeptin-10 is often sold pre-mixed or combined with other peptides. A few of these pairs appear together in published studies; each stack page lists what was tested, and the pages below cover the math and what each part has been studied for.
Common questions
Is Kisspeptin-10 FDA approved?
No. Kisspeptin-10 is not FDA approved for any use.
Is Kisspeptin-10 banned in sport?
Yes. Prohibited by WADA (S2.2.1), so it is prohibited at all times for tested athletes.
How much water goes in a 10 mg vial?
That choice only changes the concentration. With 2 mL, the vial is 5 mg/mL. The calculator converts any amount to syringe units. It does the math only and does not suggest a dose.
What is kisspeptin?
A reproductive-axis peptide: kisspeptin-10 is a potent stimulator of LH in men.[16]
What does kisspeptin do?
In a randomized trial in women with hypoactive sexual desire disorder, kisspeptin changed brain responses to sexual and facial attraction stimuli.[20]
Is there a kisspeptin nasal spray?
The trials cited used intravenous or subcutaneous administration; no nasal spray study was found.[4]
Sources
- 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 2United States: No FDA-approved product found: Drugs@FDA (openFDA) search for active ingredient "Kisspeptin-10" returned no matches on 2 Oct 2026.U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 3US compounding: Kisspeptin-10 is in FDA's 503A category 2 (significant safety risks), added 29 September 2023.U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
- 4Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men.European journal of endocrinology · 2026PMID 42549827Accessed 2 Oct 2026
- 5Kisspeptin Mitigates Hepatic De Novo Lipogenesis in Metabolic Dysfunction-Associated Steatotic Liver Disease.Cells · 2025PMID 40862768Accessed 2 Oct 2026
- 6Endocrine profile of the kisspeptin receptor agonist MVT-602 in healthy premenopausal women with and without ovarian stimulation: results from 2 randomized, placebo-controlled clinical tricals.Fertility and sterility · 2024PMID 37925096Accessed 2 Oct 2026
- 7PubMed search: ("kisspeptin-10"[tiab] OR "kisspeptin 10"[tiab]) AND humans[mh] (110 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 8PubMed search: (kisspeptin[tiab]) AND humans[mh] AND (randomized controlled trial[pt] OR clinical trial[pt]) (54 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9PubMed search: kisspeptin[tiab] AND (half-life[tiab] OR pharmacokinetic*[tiab]) AND humans[mh] (13 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10PubMed search: kisspeptin[tiab] AND humans[mh] AND (men[tiab] OR male[tiab]) AND (testosterone[tiab] OR hypogonadism[tiab]) (90 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 11PubMed search: kisspeptin[tiab] AND (menopaus*[tiab] OR postmenopaus*[tiab]) (89 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 12PubMed search: kisspeptin[tiab] AND (liver[tiab] OR NAFLD[tiab] OR hepatic[tiab]) (68 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 13PubMed search: ("kisspeptin-10"[tiab] OR "kisspeptin-54"[tiab] OR kisspeptin[tiab]) AND humans[mh] AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (75 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 14PubMed search: (kisspeptin[tiab]) AND (nausea[tiab] OR flush*[tiab] OR "injection site"[tiab] OR headache[tiab] OR "ovarian hyperstimulation"[tiab] OR tachyphylaxis[tiab] OR desensiti*[tiab]) AND humans[mh] (60 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 15PubMed search: (kisspeptin[tiab] OR "kisspeptin-54"[tiab] OR "kisspeptin-10"[tiab]) AND ("clinical trial"[pt] OR "randomized controlled trial"[pt]) AND (women[tiab] OR men[tiab]) AND (adverse[tiab] OR tolerat*[tiab] OR "side effects"[tiab]) (5 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 16Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men.The Journal of clinical endocrinology and metabolism · 2011PMID 21632807Accessed 2 Oct 2026
- 17The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans.The Journal of clinical endocrinology and metabolism · 2011PMID 21976724Accessed 2 Oct 2026
- 18Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis.The Journal of clinical endocrinology and metabolism · 2009PMID 19820030Accessed 2 Oct 2026
- 19Twice-weekly administration of kisspeptin-54 for 8 weeks stimulates release of reproductive hormones in women with hypothalamic amenorrhea.Clinical pharmacology and therapeutics · 2010PMID 20980998Accessed 2 Oct 2026
- 20Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial.JAMA network open · 2022PMID 36287566Accessed 2 Oct 2026
Found an error? Report a correction.